


## Procarbazine Hydrochloride

<b>Cat. No.:</b>	HY-13733
<b>CAS No.:</b>	366-70-1
<b>Molecular Formula:</b>	C <sub>12</sub> H <sub>20</sub> ClN <sub>3</sub> O
<b>Molecular Weight:</b>	257.76
<b>Target:</b>	DNA Alkylator/Crosslinker
<b>Pathway:</b>	Cell Cycle/DNA Damage
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (387.96 mM; Need ultrasonic)  
DMSO : 16.67 mg/mL (64.67 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.8796 mL	19.3979 mL	38.7958 mL
	5 mM	0.7759 mL	3.8796 mL	7.7592 mL
	10 mM	0.3880 mL	1.9398 mL	3.8796 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 100 mg/mL (387.96 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (8.07 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 1.67 mg/mL (6.48 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 1.67 mg/mL (6.48 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Procarbazine Hydrochloride is an orally active alkylating agent, with anticancer activity. Procarbazine Hydrochloride can be used in Hodgkin's disease research<sup>[1][2]</sup>.

#### In Vitro

Procarbazine Hydrochloride (5 and 20 nM; 1 h) treatment shows cell survival at various concentrations<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
Cell Viability Assay<sup>[1]</sup>

	Cell Line:	L1210 cells
	Concentration:	5 and 20 nM
	Incubation Time:	1 hour
	Result:	Showed 99.3% and 99.9% survival of cells at 5 mM and 20 mM, respectively.
<b>In Vivo</b>	Procarbazine (Intraperitoneal injection; 50 and 150 mg/kg; once daily; 5 d) induces micronuclei in hematopoietic cells, but not increases the lacZ mutant frequency (MF) in bone marrow <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male muta mouse (7–8 weeks old) <sup>[2]</sup>
	Dosage:	50 and 150 mg/kg
	Administration:	Intraperitoneal injection; 50 and 150 mg/kg; once daily; 5 days
	Result:	Increased the MN frequency appreciably, and observed micronucleus induction in the peripheral blood at 50 mg/kg.

## CUSTOMER VALIDATION

- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Mol Imaging Biol. 2020 Feb;22(1):124-133.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. J M Erikson, et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res. 1989 Jan 1;49(1):127-33.
- [2]. T Suzuki, et al. Procarbazine genotoxicity in the MutaMouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res. 1999 Aug 18;444(2):269-81.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA